---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-057429"
form_type: "8-K"
ticker: "ACET"
cik: "0001720580"
company_name: "Adicet Bio, Inc."
filed_at: "2024-05-10T23:59:59+00:00"
generated_at: "2026-06-02T03:57:20.684869+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Adicet presents ADI-270 preclinical data at ASGCT; IND filing expected Q2 2024

## Summary
- ADI-270 is an allogeneic anti-CD70 CAR γδ T cell therapy for solid and hematological cancers.
- Preclinical data showed potent regression in ccRCC xenografts and lower CRS potential vs αβ CAR-T.
- Armoring includes TGFβ receptor II inactivation and protection against alloreactive T cells.
- IND submission in clear cell renal cell carcinoma (ccRCC) expected Q2 2024.
- ADI-270 demonstrated both CAR-dependent and CAR-independent tumor targeting mechanisms.

## SEC filing metadata
- accession: 0000950170-24-057429
- form_type: 8-K
- ticker: ACET
- cik: 0001720580
- company_name: Adicet Bio, Inc.
- filed_at: 2024-05-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720580/000095017024057429/0000950170-24-057429-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720580/000095017024057429/acet-20240510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-057429
- JSON: https://secwatch.observer/filing/0000950170-24-057429.json
- Plain text: https://secwatch.observer/filing/0000950170-24-057429.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.